A report of a woman with depression describes improvement after clinicians recognized catatonic signs and added lorazepam. It provides a diagnostic example rather than a treatment-success estimate.
What changed in the assessment
The 58-year-old woman had already received treatment for recurrent depression and anxiety. At reassessment, clinicians identified withdrawal from activity, partial mutism, and negativism, together with poor functional and oral intake histories.
The revised formulation included catatonic features. The report describes rapid improvement after lorazepam was introduced.
One patient and several claims
The article discusses remission percentages from earlier literature, but those percentages were not measured in this case. Its suggestions concerning continuation duration likewise were not tested in a randomized comparison.
Clinical improvement after a medication can support the working assessment without proving a unique underlying mechanism. Concurrent treatment, observation, and the evolving illness remain relevant.
Applying the report
A useful chart review preserves the specific motor and behavioral signs before and after treatment, rather than treating depression alone as the indication. This case cannot show that every withdrawn patient has catatonia, that a particular maintenance duration prevents recurrence, or that the same response should occur in another patient with superficially similar symptoms.
Source paper
Original analysis of the supplied journal article, identified as PMC6406932.
Leave a Reply